Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines

Kweon, Kyeong; Ahn, Ji Yun; Song, Woo‐Jin; Li, Qiang; Lee, Bo‐Yeon; Chae, Hyung‐Kyu; Youn, Hwa‐Young

doi:10.1007/s11626-018-0294-y

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For cell cycle assay, as described previously [ 41 ], LMeC and CHMp cells were cultured in 6-well cell culture plates, allowed to adhere, and further cultured with increasing concentrations of rivoceranib (0, 12.5, and 25 μM). After 48 h, 1 × 10 5 cells were collected, washed with cold PBS, and fixed with 70% cold alcohol at -20 °C for 2 h. The cells were then collected, washed again with PBS, and incubated with 500 μL of PI/RNase buffer (BD Biosciences, San Diego, CA, USA) for 30 min at room temperature.…”

Section: Methodsmentioning

confidence: 99%

Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models

Kim

et al. 2021

BMC Vet Res

Self Cite

View full text Add to dashboard Cite

Background Rivoceranib, a novel tyrosine kinase inhibitor, exhibits anti-tumour effects by selectively blocking vascular endothelial growth factor receptor-2 (VEGFR2) in cancer cells. Recently, the therapeutic effects of rivoceranib on solid tumours have been elucidated in human patients. However, the anti-tumour effects of rivoceranib against canine cancer remain unclear. Here, we investigated the anti-tumour effects of rivoceranib using in vitro and in vivo mouse xenograft models. Methods We performed cell proliferation, cell cycle, and migration assays to determine the effects of rivoceranib on canine solid tumour cell lines in vitro. Furthermore, apoptosis and angiogenesis in tumour tissues were examined using a TUNEL assay and immunohistochemistry methods with an anti-cluster of differentiation-31 antibody, respectively. Additionally, the expression levels of cyclin-D1 and VEGFR2 activity were determined using western blot analysis. Results Rivoceranib treatment showed anti-proliferative effects and mediated cell cycle arrest in the canine melanoma cell line (LMeC) and the mammary gland tumour (MGT) cell line (CHMp). In animal experiments, rivoceranib decreased the average volume of LMeC cells compared to that following control treatment, and similar results were observed in CHMp cells. Histologically, rivoceranib induced apoptosis and exerted an anti-angiogenic effect in tumour tissues. It also downregulated the expression of cyclin-D1 and inhibited VEGFR2 activity. Conclusion Our results show that rivoceranib inhibits proliferation and migration of tumour cells. These findings support the potential application of rivoceranib as a novel chemotherapeutic strategy for canine melanoma and MGTs.

show abstract

Section: Methodsmentioning

confidence: 99%